FAS Antibody - #AF6695
| 製品: | FAS Antibody |
| カタログ: | AF6695 |
| タンパク質の説明: | Rabbit polyclonal antibody to FAS |
| アプリケーション: | ELISA(peptide) |
| 反応性: | Human |
| 分子量: | 38kD(Calculated). |
| ユニプロット: | P25445 |
| RRID: | AB_2847418 |
製品説明
*The optimal dilutions should be determined by the end user.
*Tips:
WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.
引用形式: Affinity Biosciences Cat# AF6695, RRID:AB_2847418.
折りたたみ／展開
ALPS 1A; ALPS1A; APO 1; Apo 1 antigen; APO 1 cell surface antigen; Apo-1 antigen; APO1; Apo1 antigen; APO1 cell surface antigen; Apoptosis antigen 1; Apoptosis mediating surface antigen FAS; Apoptosis-mediating surface antigen FAS; APT 1; APT1; CD 95; CD 95 antigen; CD95; CD95 antigen; Delta Fas; Delta Fas/APO 1/CD95; Delta Fas/APO1/CD95; Fas (TNF receptor superfamily, member 6); FAS 1; FAS 827dupA; Fas AMA; Fas; FAS Antigen; Fas cell surface death receptor; FAS1; FASLG receptor; FASTM; sFAS; Surface antigen APO1; TNF receptor superfamily, member 6; TNFRSF 6; TNFRSF6; TNR6_HUMAN; Tumor necrosis factor receptor superfamily member 6;
免疫原
A synthesized peptide derived from human FAS.
Isoform 1 and isoform 6 are expressed at equal levels in resting peripheral blood mononuclear cells. After activation there is an increase in isoform 1 and decrease in the levels of isoform 6.
- P25445 TNR6_HUMAN:
- Protein BLAST With
- NCBI/
- ExPASy/
- Uniprot
MLGIWTLLPLVLTSVARLSSKSVNAQVTDINSKGLELRKTVTTVETQNLEGLHHDGQFCHKPCPPGERKARDCTVNGDEPDCVPCQEGKEYTDKAHFSSKCRRCRLCDEGHGLEVEINCTRTQNTKCRCKPNFFCNSTVCEHCDPCTKCEHGIIKECTLTSNTKCKEEGSRSNLGWLCLLLLPIPLIVWVKRKEVQKTCRKHRKENQGSHESPTLNPETVAINLSDVDLSKYITTIAGVMTLSQVKGFVRKNGVNEAKIDEIKNDNVQDTAEQKVQLLRNWHQLHGKKEAYDTLIKDLKKANLCTLAEKIQTIILKDITSDSENSNFRNEIQSLV
PTMs - P25445 基板として
| Site | PTM Type | Enzyme | Source |
|---|---|---|---|
| T28 | O-Glycosylation | Uniprot | |
| K33 | Ubiquitination | Uniprot | |
| T40 | O-Glycosylation | Uniprot | |
| T42 | O-Glycosylation | Uniprot | |
| T43 | O-Glycosylation | Uniprot | |
| T46 | O-Glycosylation | Uniprot | |
| Y91 | Phosphorylation | Uniprot | |
| N118 | N-Glycosylation | Uniprot | |
| K204 | Ubiquitination | Uniprot | |
| S209 | Phosphorylation | Uniprot | |
| S212 | Phosphorylation | Uniprot | |
| T214 | Phosphorylation | Uniprot | |
| T219 | Phosphorylation | Uniprot | |
| S225 | Phosphorylation | Uniprot | |
| S230 | Phosphorylation | Uniprot | |
| Y232 | Phosphorylation | Uniprot | |
| T234 | Phosphorylation | Uniprot | |
| T241 | Phosphorylation | Uniprot | |
| S243 | Phosphorylation | Uniprot | |
| K263 | Ubiquitination | Uniprot | |
| K274 | Ubiquitination | Uniprot | |
| K287 | Ubiquitination | Uniprot | |
| K288 | Ubiquitination | Uniprot | |
| Y291 | Phosphorylation | Uniprot | |
| T293 | Phosphorylation | Uniprot | |
| K296 | Ubiquitination | Uniprot | |
| K300 | Ubiquitination | Uniprot | |
| T305 | Phosphorylation | Uniprot | |
| K309 | Ubiquitination | Uniprot | |
| T312 | Phosphorylation | Uniprot | |
| K316 | Ubiquitination | Uniprot | |
| S320 | Phosphorylation | Uniprot | |
| S322 | Phosphorylation | Uniprot | |
| S325 | Phosphorylation | Uniprot | |
| S333 | Phosphorylation | Uniprot |
研究背景
Receptor for TNFSF6/FASLG. The adapter molecule FADD recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. FAS-mediated apoptosis may have a role in the induction of peripheral tolerance, in the antigen-stimulated suicide of mature T-cells, or both. The secreted isoforms 2 to 6 block apoptosis (in vitro).
N- and O-glycosylated. O-glycosylated with core 1 or possibly core 8 glycans.
Cell membrane>Single-pass type I membrane protein.
Secreted.
Secreted.
Secreted.
Secreted.
Secreted.
Isoform 1 and isoform 6 are expressed at equal levels in resting peripheral blood mononuclear cells. After activation there is an increase in isoform 1 and decrease in the levels of isoform 6.
Binds DAXX. Interacts with HIPK3 (By similarity). Part of a complex containing HIPK3 and FADD (By similarity). Binds RIPK1 and FAIM2. Interacts with BABAM2 and FEM1B. Interacts with FADD. Interacts directly (via DED domain) with NOL3 (via CARD domain); inhibits death-inducing signaling complex (DISC) assembly by inhibiting the increase in FAS-FADD binding induced by FAS activation (By similarity). Interacts with CALM. In the absence of stimulation, interacts with BIRC2, DDX3X and GSK3B. The interaction with BIRC2 and DDX3X is further enhanced upon receptor stimulation and accompanied by DDX3X and BIRC2 cleavage.
Contains a death domain involved in the binding of FADD, and maybe to other cytosolic adapter proteins.
研究領域
· Cellular Processes > Cell growth and death > p53 signaling pathway. (View pathway)
· Cellular Processes > Cell growth and death > Apoptosis. (View pathway)
· Cellular Processes > Cell growth and death > Necroptosis. (View pathway)
· Environmental Information Processing > Signal transduction > MAPK signaling pathway. (View pathway)
· Environmental Information Processing > Signaling molecules and interaction > Cytokine-cytokine receptor interaction. (View pathway)
· Environmental Information Processing > Signal transduction > TNF signaling pathway. (View pathway)
· Human Diseases > Drug resistance: Antineoplastic > Platinum drug resistance.
· Human Diseases > Endocrine and metabolic diseases > Non-alcoholic fatty liver disease (NAFLD).
· Human Diseases > Endocrine and metabolic diseases > Type I diabetes mellitus.
· Human Diseases > Neurodegenerative diseases > Alzheimer's disease.
· Human Diseases > Infectious diseases: Parasitic > Chagas disease (American trypanosomiasis).
· Human Diseases > Infectious diseases: Parasitic > African trypanosomiasis.
· Human Diseases > Infectious diseases: Viral > Hepatitis B.
· Human Diseases > Infectious diseases: Viral > Measles.
· Human Diseases > Infectious diseases: Viral > Influenza A.
· Human Diseases > Infectious diseases: Viral > Human papillomavirus infection.
· Human Diseases > Infectious diseases: Viral > Herpes simplex infection.
· Human Diseases > Cancers: Overview > Pathways in cancer. (View pathway)
· Human Diseases > Cancers: Overview > Proteoglycans in cancer.
· Human Diseases > Immune diseases > Autoimmune thyroid disease.
· Human Diseases > Immune diseases > Allograft rejection.
· Human Diseases > Immune diseases > Graft-versus-host disease.
· Organismal Systems > Immune system > Natural killer cell mediated cytotoxicity. (View pathway)
Restrictive clause
Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.
For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.